Shopping Cart
Remove All
Your shopping cart is currently empty
Ianalumab (Synonyms: VAY-736)
Catalog No. T77370 Copy Product Info
🥰Excellent
Ianalumab (VAY-736) is a decarboxylated humanized antibody against BAFF-R that inhibits the interaction between BAFF and BAFF-R, blocking BAFF-mediated apoptosis protection. Ianalumab exhibits antibody-dependent cytotoxicity (ADCC) and activates effector cells via the immune receptor tyrosine activation motif (ITAM).
Ianalumab
Copy Product Info🥰Excellent
Catalog No. T77370
Synonyms VAY-736
Ianalumab (VAY-736) is a decarboxylated humanized antibody against BAFF-R that inhibits the interaction between BAFF and BAFF-R, blocking BAFF-mediated apoptosis protection. Ianalumab exhibits antibody-dependent cytotoxicity (ADCC) and activates effector cells via the immune receptor tyrosine activation motif (ITAM).
Ianalumab
Cas No. 1929549-92-7
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $222 | - | In Stock | |
| 5 mg | $553 | - | In Stock | |
| 10 mg | $796 | - | In Stock | |
| 25 mg | $1,220 | - | In Stock | |
| 50 mg | $1,650 | - | In Stock | |
| 100 mg | $2,220 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:100% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ianalumab (VAY-736) is a decarboxylated humanized antibody against BAFF-R that inhibits the interaction between BAFF and BAFF-R, blocking BAFF-mediated apoptosis protection. Ianalumab exhibits antibody-dependent cytotoxicity (ADCC) and activates effector cells via the immune receptor tyrosine activation motif (ITAM). |
| In vitro | Ianalumab (0.1 μg/mL; 72 h) demonstrates significant antibody-dependent cell-mediated cytotoxicity (ADCC) against natural killer cells in chronic lymphocytic leukemia (CLL), enhancing cytokine production[1]. |
| In vivo | Ianalumab (total dose: 100 mg/kg; once a week; for 2 weeks) increases the survival rate in a mouse model of chronic lymphocytic leukemia (CLL)[1]. Ianalumab (10 mg/kg; once a week; for 6 weeks), when modulated with Ibrutinib, demonstrates enhanced functionality of NK cells[1]. |
| Synonyms | VAY-736 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF13C/BAFFR/CD268 |
| Molecular Weight | 146.44 kDa |
| Cas No. | 1929549-92-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Ianalumab | purchase Ianalumab | Ianalumab cost | order Ianalumab | Ianalumab in vivo | Ianalumab in vitro | Ianalumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.